Literature DB >> 8052479

Comparison of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas.

T Takada1, H Kato, T Matsushiro, Y Nimura, T Nagakawa, T Nakayama.   

Abstract

In this multicenter randomized trial, the efficacy of combination chemotherapy using 5-fluorouracil, doxorubicin and mitomycin C (arm A) was compared with that of 5-fluorouracil alone (arm B) in 81 patients with nonresectable carcinomas of the pancreas or biliary tract. There were no significant differences between treatment arms regarding the median time to progressive disease, median survival time, palliative effects or toxicities. It was concluded that combination chemotherapy is feasible but cannot be recommended.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8052479     DOI： 10.1159/000227373

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


  18 in total

Review 1.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

Review 2.  Cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Ghulam Abbas; Keith D Lindor
Journal:  J Gastrointest Cancer       Date:  2009-08-25

3.  Long-term survival of patients with gallbladder cancer detected during or after laparoscopic cholecystectomy.

Authors:  Tomotaka Akatsu; Masakazu Ueda; Motohide Shimazu; Go Wakabayashi; Koichi Aiura; Minoru Tanabe; Shigeyuki Kawachi; Hiromu Kido; Masaki Kitajima
Journal:  World J Surg       Date:  2005-09       Impact factor: 3.352

Review 4.  Signaling pathways as therapeutic targets in biliary tract cancer.

Authors:  Jennifer Yang; Matthew R Farren; Daniel Ahn; Tanios Bekaii-Saab; Gregory B Lesinski
Journal:  Expert Opin Ther Targets       Date:  2017-03-17       Impact factor: 6.902

Review 5.  Current management of gallbladder carcinoma.

Authors:  Andrew X Zhu; Theodore S Hong; Aram F Hezel; David A Kooby
Journal:  Oncologist       Date:  2010-02-10

6.  Surgery and chemotherapy for intrahepatic cholangiocarcinoma.

Authors:  Zenichi Morise; Atsushi Sugioka; Takamasa Tokoro; Yoshinao Tanahashi; Yasuhiro Okabe; Tadashi Kagawa; Chinatsu Takeura
Journal:  World J Hepatol       Date:  2010-02-27

7.  Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.

Authors:  Nikolas Tsavaris; Christos Kosmas; Panagiotis Gouveris; Kostadinos Gennatas; Aris Polyzos; Despina Mouratidou; Heracles Tsipras; Helias Margaris; George Papastratis; Evanthia Tzima; Nikitas Papadoniou; Gavrilos Karatzas; Efstathios Papalambros
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

8.  Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma.

Authors:  Chaiyut Charoentum; Sumitra Thongprasert; Busyamas Chewaskulyong; Sutthirak Munprakan
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

9.  Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.

Authors:  Agustin A Garcia; Lawrence Leichman; Joaquina Baranda; Lalita Pandit; Heinz-Josef Lenz; Cynthia G Leichman
Journal:  Int J Gastrointest Cancer       Date:  2003

10.  Guidelines for chemotherapy of biliary tract and ampullary carcinomas.

Authors:  Junji Furuse; Tadahiro Takada; Masaru Miyazaki; Shuichi Miyakawa; Kazuhiro Tsukada; Masato Nagino; Satoshi Kondo; Hiroya Saito; Toshio Tsuyuguchi; Koichi Hirata; Fumio Kimura; Hideyuki Yoshitomi; Satoshi Nozawa; Masahiro Yoshida; Keita Wada; Hodaka Amano; Fumihiko Miura
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.